VivoSim Labs, Inc. received a Nasdaq delisting notice due to failing to meet the $2.5 million minimum stockholders' equity requirement. The company has until September 3, 2026, to submit a compliance plan, though recent capital raises and a $5.0 million milestone payment from Eli Lilly and Company have brought stockholders' equity above the $2.5 million threshold. VivoSim Labs, Inc. is a biotechnology company focused on developing FXR assets.

VivoSim Labs, Inc. entered into a Securities Purchase Agreement with a healthcare-focused institutional investor for a private placement of pre-funded warrants and accompanying warrants to purchase up to 4,705,883 shares of common stock. The transaction carries a combined purchase price of $0.85 per share, generating approximately $4.0 million in gross proceeds. The company will use the funds for working capital and general corporate purposes. Additionally, the company amended existing warrants held by Armistice Capital Master Fund Ltd. to reduce their exercise price from $9.60 to $0.85 per share, subject to stockholder approval. A.G.P./Alliance Global Partners is serving as the placement agent with a 6.50% cash fee. VivoSim Labs is a biotechnology services company providing 3D human cellular models for preclinical safety testing.